Updating results

254 results

Sort: Relevance | Date

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

This guidance has been updated and replaced by NICE technology appraisal guidance 531.

Technology appraisal guidance Published June 2017

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

This guidance has been updated and replaced by NICE technology appraisal guidance 524.

Technology appraisal guidance Published June 2017

Daclizumab for treating relapsing–remitting multiple sclerosis (TA441)

This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.

Technology appraisal guidance Published April 2017

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

This guidance has been updated and replaced by NICE technology appraisal guidance 616.

Technology appraisal guidance Published December 2017